Live
Endpoints NewsModerna in talks with FDA over Phase 4 Covid vaccine dataEndpoints NewsFDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming dataEndpoints NewsAmgen launches late-stage obesity trial in patients who switch from rival drugsFierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPOBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 30, 2026Endpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchBioPharma DiveSummit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBioPharma DiveModerna sees revenue bump from international COVID vaccine salesEndpoints NewsSamsung Biologics workers begin five-day strike over wage disputesBioWorldIn the clinic for May 1, 2026BioWorldOther news to note for May 1, 2026
BioPharma Dive Mar 17, 2026

R1 starts up with $78M, aiming for a better kidney drug

R1 starts up with $78M, aiming for a better kidney drug

Original
Body unavailable. Use the original source.